Straits Times Index
3,298.94 +8.24 (+0.25%) Nikkei
38,100.25 -128.86 (-0.34%) Hang Seng
19,044.98 +81.30 (+0.43%) FTSE 100
8,433.76 +261.61 (+3.20%) Bitcoin USD
60,943.66 -62.09 (-0.10%) CMC Crypto 200
1,257.44 -55.19 (-4.20%)
Ocular Therapeutix, Inc. (0OT.F)
| Previous close | 5.40 |
| Open | 5.37 |
| Bid | 0.00 x 140000 |
| Ask | 0.00 x 140000 |
| Day's range | 5.20 - 5.37 |
| 52-week range | 1.88 - 10.81 |
| Volume | |
| Avg. volume | 952 |
| Market cap | 813.234M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Ocular Therapeutix™ Reports First Quarter 2024 Results
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a bi
- GlobeNewswire
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has agreed to grant inducement awards to (i) its newly appointed Vice President, Head of Programmin
- GlobeNewswire
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it will participate at two investor conferences in May: Citizens JMP Life Sciences Confe
